Assessing additional benefit in noninferiority trials

被引:4
作者
Kieser, Meinhard [1 ]
Stucke, Kathrin [1 ]
机构
[1] Heidelberg Univ, Inst Med Biometry & Informat, D-69120 Heidelberg, Germany
关键词
Additional benefit; Average type I error rate; Coprimary endpoints; Multiplicity; Noninferiority trials; GOLD STANDARD DESIGN; PRIMARY END-POINTS; NON-INFERIORITY TRIALS; EQUIVALENCE RANDOMIZED-TRIALS; SAMPLE-SIZE DETERMINATION; ESTABLISHING EFFICACY; CLINICAL-TRIALS; SUPERIORITY; STATISTICS; QUALITY;
D O I
10.1002/bimj.201300227
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
A method for simultaneously assessing noninferiority with respect to efficacy and superiority with respect to another endpoint in two-arm noninferiority trials is presented. The procedure controls both the average type I error rate for the intersection-union test problem and the frequentist type I error rate for the noninferiority test by a while allowing an increased level for the superiority test. For normally distributed outcomes, two methods are presented to deal with the uncertainty about the correlation between the endpoints which defines the adjusted levels. The operating characteristics of these procedures are investigated. Furthermore, the sample size required when applying the proposed method is compared with that of alternative procedures. Application of the method in the situation of binary endpoints and mixed normal and binary endpoints, respectively, is sketched. An illustrative example is provided demonstrating implementation of the proposed approach in a clinical trial.
引用
收藏
页码:154 / 169
页数:16
相关论文
共 39 条
  • [1] [Anonymous], GUID IND NO IN PRESS
  • [2] [Anonymous], 2012, R LANG ENV STAT COMP
  • [3] World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care
    Bauer, Michael
    Bschor, Tom
    Pfennig, Andrea
    Whybrow, Peter C.
    Angst, Jules
    Versiani, Marcio
    Moeller, Hans-Juergen
    [J]. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2007, 8 (02) : 67 - 104
  • [4] Bauer P, 2001, METHOD INFORM MED, V40, P117
  • [5] Phase IV non-inferiority trials and additional claims of benefit
    Bernabe, Rosemarie D. L. C.
    Wangge, Grace
    Knol, Mirjam J.
    Klungel, Olaf H.
    van Delden, Johannes J. M.
    de Boer, Anthonius
    Hoes, Arno W.
    Raaijmakers, Jan A. M.
    van Thiel, Ghislaine J. M. W.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2013, 13
  • [6] A combined superiority and non-inferiority approach to multiple endpoints in clinical trials
    Bloch, Daniel A.
    Lai, Tze Leung
    Su, Zheng
    Tubert-Bitter, Pascale
    [J]. STATISTICS IN MEDICINE, 2007, 26 (06) : 1193 - 1207
  • [7] CHMP, 2010, REFL PAP NEED ACT CO
  • [8] Challenge of multiple co-primary endpoints: A new approach
    Chuang-Stein, Christy
    Stryszak, Paul
    Dmitrienko, Alex
    Offen, Walter
    [J]. STATISTICS IN MEDICINE, 2007, 26 (06) : 1181 - 1192
  • [9] Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics
    D'Agostino, RB
    Massaro, JM
    Sullivan, LM
    [J]. STATISTICS IN MEDICINE, 2003, 22 (02) : 169 - 186
  • [10] OUTLOOK Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
    Eichler, Hans-Georg
    Bloechl-Daum, Brigitte
    Abadie, Eric
    Barnett, David
    Koenig, Franz
    Pearson, Steven
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (04) : 277 - 291